Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

March 25, 2026

AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026

March 25, 2026

Toll Brothers Announces Final Opportunity to Purchase a New Home at Lakeview Estates in Lehi, Utah

March 25, 2026

2026 Canadian Screen Awards nominations: ‘North of North,’ ’40 Acres’ lead pack

March 25, 2026

APO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Apollo Global Management (APO) Investors of Securities Class Action Deadline on May 1, 2026

March 25, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » The ROOT Brands® Introduces CRUSH and SCULPT as a Smart, Non Drug Wellness Path Before, After or During Synthetic GLPs
Press Release

The ROOT Brands® Introduces CRUSH and SCULPT as a Smart, Non Drug Wellness Path Before, After or During Synthetic GLPs

By News RoomMarch 25, 20263 Mins Read
The ROOT Brands® Introduces CRUSH and SCULPT as a Smart, Non Drug Wellness Path Before, After or During Synthetic GLPs
Share
Facebook Twitter LinkedIn Pinterest Email

Franklin Tennessee, March 25, 2026 (GLOBE NEWSWIRE) — As GLP‑1 medications continue to rise across the United States, many consumers now face the same question after injections begin or end: What supports the body next?

ROOT Brands® answers with CRUSH™ and SCULPT™, two proven and natural science‑driven wellness formulas designed to support metabolic balance, body composition, and cellular health without drugs, hormones, or synthetic injections.

Together, CRUSH and SCULPT provide a natural next step for individuals seeking structure, support, and sustainability during or after GLP‑1 use.

The GLP Gap Solved

Synthetic GLP medications focus on appetite reduction and blood sugar signaling. They do not build muscle, optimize cellular pathways, or support long‑term metabolic resilience.

Many individuals report new challenges after injections, ROOT Crush and Sculpt solve these by:

  • Improving lean muscle mass
  • Improving metabolism
  • Increasing energy
  • Resolving digestive disruption
  • Maintaining and continuing improvements once medication injections stop

ROOT Brands® developed CRUSH and SCULPT to address these gaps through natural bioscience engineered cellular‑level support.

What CRUSH™ Supports

CRUSH is designed to support metabolic efficiency, mitochondrial performance, and daily fat utilization through non‑stimulant, nutrition‑based pathways.

CRUSH supports:

  • Healthy metabolic function
  • Cellular energy production
  • Natural fat utilization
  • Daily vitality without appetite suppression drugs

CRUSH does not force hunger signals or override the body. It supports cellular processes allowing metabolism to function as designed.

What SCULPT™ Supports

SCULPT focuses on lean body composition and muscle preservation, two areas commonly impacted during GLP‑1 use.

SCULPT supports:

  • Lean muscle maintenance
  • Body composition balance
  • Physical strength and tone
  • Recovery and performance support

Muscle serves as a metabolic engine. SCULPT helps protect and support muscle integrity while individuals work toward sustainable wellness.

A Cellular‑First Philosophy

ROOT Brands® approaches wellness through cellular health first, following a simple principle:

Clean the cell → Feed the cell → Protect the cell

CRUSH and SCULPT fit directly into this framework by supporting:

  • Clean cellular pathways
  • Efficient nutrient use
  • Strong mitochondria
  • Long‑term metabolic resilience

This approach complements lifestyle changes, nutrition, and movement rather than replacing them.

A Non‑Drug Option for Sustainable Results

CRUSH and SCULPT are not medications. They make no medical claims and do not treat disease.

They provide a drug‑free option for people who:

  • Want support after GLP‑1 injections
  • Are transitioning off GLP‑1 medications
  • Prefer non‑injectable wellness solutions
  • Seek long‑term metabolic and body composition support

Availability

CRUSH™ and SCULPT™ are available exclusively through ROOT Brands®.

Learn more:

About ROOT Brands

CRUSH and SCULPT were created by Dr. Christina Rahm and developed under ROOT Brands® by CEO Clayton Thomas. These formulations reflect a science‑forward, non‑drug approach to modern wellness innovation.
To learn more about CRUSH and SCULPT, or to request an interview with Dr. Christina Rahm or CEO Clayton Thomas, please contact ROOT Brands® for additional information.  Visit the ROOT Brands Here

  • SCULPT Precision Cellular Support for Lean Body Optimization
  • CRUSH Cellular Reset Nutrition Supporting Metabolic Momentum
            
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026

Toll Brothers Announces Final Opportunity to Purchase a New Home at Lakeview Estates in Lehi, Utah

APO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Apollo Global Management (APO) Investors of Securities Class Action Deadline on May 1, 2026

Pure DC and SEGRO Unlock Major AI Infrastructure Development in London

TCPC INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds BlackRock TCP Capital Investors of the Securities Class Action Lawsuit Deadline on April 6, 2026

BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026

SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

LU INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Lufax (LU) Investors of Securities Class Action Deadline on May 20, 2026

Editors Picks

AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026

March 25, 2026

Toll Brothers Announces Final Opportunity to Purchase a New Home at Lakeview Estates in Lehi, Utah

March 25, 2026

2026 Canadian Screen Awards nominations: ‘North of North,’ ’40 Acres’ lead pack

March 25, 2026

APO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Apollo Global Management (APO) Investors of Securities Class Action Deadline on May 1, 2026

March 25, 2026

Latest News

You can install these wireless security cameras over half a mile away

March 25, 2026

Pure DC and SEGRO Unlock Major AI Infrastructure Development in London

March 25, 2026

TCPC INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds BlackRock TCP Capital Investors of the Securities Class Action Lawsuit Deadline on April 6, 2026

March 25, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version